Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of February 2021 for Enlivex Therapeutics Ltd., an Israeli company. The filing primarily addresses updates regarding an At-the-Market (ATM) Sales Agreement entered into on October 22, 2020, with H.C. Wainwright & Co., LLC as the sales agent.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The only specific financial data disclosed relates to the ATM Offering:
- Total ATM Offering Capacity: Up to $25.0 million.
- Shares Sold to Date: 476,983 ordinary shares.
- Aggregate Proceeds to Date: $8,315,223.
Material Changes
On February 9, 2021, the Company terminated the Prospectus Supplement dated October 22, 2020, which governed the ATM Offering. However, the underlying Offering Agreement remains in full force and effect, allowing the Company to continue selling shares under the agreement.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the ATM Offering status. The termination of the Prospectus Supplement is noted as a procedural update rather than a strategic shift in the offering agreement itself.
Investor Verification Checklist
- Verify the current status of the Offering Agreement and whether new prospectus supplements have been filed to resume sales.
- Confirm the total number of shares outstanding and the dilution impact of the 476,983 shares sold.
- Review subsequent filings for any new capital raise activities or changes in the ATM program structure.
- Check for updated financial statements in the Company's Form 20-F to assess liquidity and cash position, as this 6-K does not provide them.